AnaptysBio - Home
About
Overview
Strategy
Management
Board of Directors
Therapeutic Advisory Board
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Etokimab
ANB019
ANB030
Partnerships
Clinical Trials
Investors / News
Overview
News
Events
Goverance
Stock Information
Analyst Coverage
SEC Filings
FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Toggle
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
June 5, 2019
Proof-of-Concept Phase-2a Clinical Trial of Etokimab (Anti-IL-33 Antibody) in the Treatment of Severe Eosinophilic Asthma
Proof-of-Concept Phase-2a Clinical Trial of Etokimab (Anti-IL-33 Antibody) in the Treatment of Severe Eosinophilic Asthma
May 7, 2019
AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates
AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates
About
Technology
Pipeline
Investors
Careers
